Efficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis
A Single-Centre, Single-Arm Study on the Efficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Lingli Dong, Professor
- Phone Number: 0086-027-83665519
- Email: tjhdongll@163.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430000
- Tongji Hospital, Tong ji Medical Colledge
-
Contact:
- Lingli Dong, Professor
- Phone Number: 0086-027-83665519
- Email: tjhdongll@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-70 years (inclusive), male or female.
- Diagnosis of systemic sclerosis (SSc) according to the 2013 ACR/EULAR diagnostic criteria.
- Disease duration of diffuse cutaneous systemic sclerosis (dcSSc), as defined by LeRoy & Medsger (2001), of ≤ 5 years (from the time of first onset of non-Raynaud's phenomenon).
- Modified Rodnan skin score (mRSS) ≥10;
- Voluntarily signed informed consent form and ability to comply with the requirements of the study protocol.
Exclusion Criteria:
- Allergy to the active ingredient of Firsekibart or any of its excipients, or a history of allergy to monoclonal antibodies.
- Presence of any rheumatic disease other than SSc.
- Moderate to severe lung disease with FVC < 60% or DLCO < 50% of predicted value.
- Use of medications that may interfere with the evaluation of the efficacy and safety of Firsekibart, except for stable use of permitted concomitant therapies that have been maintained for at least 4 weeks prior to screening and are kept at a stable dose throughout the study period.
- Use of biological agents or stem cell therapy within 3 months prior to screening or within 5 half-lives of the known drug.
- Receipt of live or attenuated vaccines within two months prior to screening.
- Severe hepatic impairment, renal impairment, or hematologic abnormalities at screening.
- Acute or chronic infection (excluding infection complicated by finger ulceration), active infection, history of malignant tumor, or immunodeficiency disorder.
- Women who are pregnant or breastfeeding, or subjects planning to become pregnant during the study period.
- Any other conditions that, in the investigator's judgment, render the subject ineligible for this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Firsekibart injection
Eligible participants will be enrolled and receive Firsekibart 200 mg administered subcutaneously at weeks 0, 4, and 8.
|
Firsekibart, independently developed by GeneScience, was officially approved for marketing by the NMPA in July 2025 as China's first domestically developed fully human monoclonal antibody targeting IL-1β.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the modified Rodnan Skin Score (mRSS) from baseline
Time Frame: Week 12
|
The mRSS is independently assessed by two physicians, evaluating the thickness of skin in 17 anatomic areas rated from 0 to 3, with a total score ranging from 0 to 51.
|
Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in modified Rodnan skin score (mRSS) from baseline
Time Frame: Week 16, 24
|
The mRSS is independently assessed by two physicians, evaluating the thickness of skin in 17 anatomic areas rated from 0 to 3, with a total score ranging from 0 to 51.
|
Week 16, 24
|
|
Change in the Composite Response Index in Systemic Sclerosis (CRISS) from baseline
Time Frame: Week 12, 16, 24
|
CRISS is a weighted score and includes five core set measures: modified Rodnan skin score, FVC% predicted, health assessment questionnaire-disability index, and patient and clinician global assessments.
|
Week 12, 16, 24
|
|
Change from baseline in pulmonary function (FVC)
Time Frame: Week 12, 16, 24
|
Forced vital capacity (FVC) is the amount of air that can be forcibly exhaled after the deepest possible breath.
|
Week 12, 16, 24
|
|
Change from baseline in pulmonary function (DLCO)
Time Frame: Week 12, 16, 24
|
Diffusing capacity of the lungs for carbon monoxide (DLCO)is a key measure of gas diffusion across the alveolar-capillary membrane, determined by the single-breath method.
|
Week 12, 16, 24
|
|
Change in serum IL-1β levels from baseline
Time Frame: Week 12, 16, 24
|
IL-1β plays an important role in inflammation and fibrosis, and its expression is aberrantly regulated in various autoimmune diseases.
IL-1β is considered an effective target for diseases associated with fibrosis and tissue remodeling.
|
Week 12, 16, 24
|
|
Change in serum IL-6 levels from baseline
Time Frame: Week 12, 16, 24
|
IL-1β acts as a potent upstream stimulus for IL-6 production.
IL-6 activates fibroblasts, promoting their proliferation and driving the abundant synthesis of collagen and extracellular matrix components.
In parallel, IL-6 induces endothelial-to-mesenchymal transition in endothelial cells, thereby exacerbating the vicious cycle between microvascular pathology and fibrosis.
|
Week 12, 16, 24
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TJ-IRB202601060
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.